References
- Pfreundschuh M G, Trumper L, Ma D, Osterborg A, Pattengell R, Trneny M, et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. J Clin Oncol 2004; 22(14 suppl)6500, (Meeting Abstracts)
- Sehn L H, Donaldson J, Chhanabhai M, Fizgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23(22)5027–5033
- McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8)2825–2833
- Alexandrescu D T, Dutcher J P, O'Boyle K, Albulak M, Oiseth S, Wiernik P H. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45(11)2321–2325
- Swords R, Power D, Fay M, O'Donnell R, Murphy P T. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004; 77(1)103–104
- Leon R J, Gonsalvo A, Salas R, Hidalgo N C. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004; 79(7)949–953
- Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348(26)2690–2691
- Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005; 81(2)169–170
- Law L, Tuscano J, Wun T, Ahlberg K, Richman C. Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia. Int J Hematol 2002; 76(4)360–364
- Meyer R M, Gyger M, Langley R, Lesperance B, Caplan S N. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1998; 30(5 – 6)591–600
- Hasegawa Y, Ninomiya H, Kamoshita M, Ohtani K, Kobayashi T, Kojima H, et al. Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma. Intern Med 1997; 36(5)360–364
- Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A C, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104(3)626–633
- Kanelli S, Ansell S M, Habermann T M, Inwards D J, Tuinstra N, Witzig T E. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001; 42(6)1329–1337
- Byrd J C, Gribben J G, Peterson B L, Grever M R, Lozanski G, Lucas D M, et al. Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy. J Clin Oncol 2005; 24: 437–443
- Hainsworth J D, Litchy S, Lamb M R, Rodriguez G I, Scroggin C, Jr, Greco F A. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma 2003; 4(1)36–42